A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. (3rd October 2015)

• Record Type: Journal Article
• Authors: Sharma, Mayank Kumar; Murumkar, Prashant R; Barmade, Mahesh A; Giridhar, Rajani; Yadav, Mange Ram
• Is Part Of: Expert opinion on therapeutic patents. Volume 25:Number 10(2015:Oct.)
• Page Start: 1093
• Page End: 1116
• Publication Date: 2015-10-03
• Subjects: cannabinoid -- CB1 receptor antagonists -- endocannabinoid system -- obesity -- peripherally acting -- rimonabant; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1517/13543776.2015.1064898
• Languages: English
• ISSNs: 1354-3776

Abstract

Abstract : Introduction: Obesity is a rapidly expanding worldwide health problem. Various targets are investigated presently for the treatment of obesity, but there remains an unmet need for an effective drug therapy with acceptable efficacy levels and reduced side effects. Targeting peripherally located cannabinoid 1 (CB1) receptors is an attractive strategy as these receptors play a vital role in energy homeostasis. Areas covered: CB1 receptor antagonists constitute one of the most important categories of compounds of interest for the control of obesity. In this review, the authors focus on recent advances (since 2007) in diverse chemical classes of patented compounds belonging to the category of CB1 receptor antagonists. Expert opinion: Safer CB1 receptor antagonists for the treatment of obesity can be discovered by developing such compounds that act peripherally. Increasing the polar service area, decreasing the lipophilicity and designing of neutral antagonists and allosteric inhibitors are some interesting strategies that could offer promising results.